Press Release

DiaSorin Launches LIAISON® MeMed BV®, The First High Throughput Blood Test to Differentiate Between Bacterial and Viral Infections, in Countries Accepting the CE Mark

- LIAISON® MeMed BV® is an Immune System Based Protein Signature Test for Distinguishing Between Bacterial and Viral Infections
- The test was developed following the Licensing Agreement signed with MeMed as announced in September 2020
- The new test is available on the LIAISON® XL platforms in countries that accept CE Mark and U.S. Food and Drug Administration clearance is planned for 2022

Saluggia (Italy) and Haifa (Israel) November 23, 2021 - DiaSorin (FTSE MIB: DIA) and MeMed announced today the launch, in countries accepting CE Mark, of the novel, host-protein signature-based assay LIAISON® MeMed BV®.

The launch follows a Licensing Agreement signed with MeMed that was announced in September 2020, under which DiaSorin obtained the rights to commercialize and make the MeMed BV® test available on the extensive installed base of LIAISON® XL and LIAISON® XS platforms.

The LIAISON® MeMed BV® test is the first fully automated solution, which utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting fast and better-informed treatment and patient management decisions. The test also drives laboratory operational efficiency through time-labor reduction by using a fully automated and high-throughput approach.

The availability of this innovative test provides a valuable tool in the growing global threat posed by antimicrobial resistance (AMR). According to the World Health Organization, AMR is in fact, one of the top 10 global public health threats for humanity and it is estimated to kill 700,000 people a year worldwide, 33,000 across the EU alone. Distinguishing between bacterial and viral etiologies in acute infections has been a universal challenge for health care providers. Current practices such as medical history, physical findings and other medical tests provide incomplete answers, especially when the infection site is inaccessible. By relying on the immune response, rather than direct pathogen detection, the LIAISON® MeMed BV® test complements conventional technologies, providing actionable information and better informed antibiotic and antiviral treatment decisions, allowing for rapid and accurate diagnosis.

The LIAISON® MeMed BV® test expands DiaSorin’s market leading menu of fully-automated, chemiluminescent immunoassay panels for the diagnosis of infectious diseases and highlights the Group’s efforts to develop innovative, fully automated diagnostic solutions, with the aim of optimizing laboratory efficiency and clinical decision-making.

The LIAISON® MeMed BV® U.S. Food and Drug Administration clearance is planned for 2022.

“The novel test launched today with MeMed on our extensive installed base of LIAISON® XL platforms is strategic for our future and provides laboratories and clinicians with an innovative diagnostic tool. The test provides significant clinical value that will support accurate and informed decisions for patients, accelerating their path to recovery”, said Mr. Carlo Rosa, CEO of DiaSorin. “We are pleased to announce the launch of this new product during the World Antimicrobial Awareness Week. In line with the 2021 initiative motto “Spread awareness, stop resistance”, DiaSorin is now both increasing awareness of this current threat and actively contributing to efforts to stop antimicrobial resistance”.

“The launch of the LIAISON® MeMed BV® test by DiaSorin is a significant milestone in our long-term vision to drive game-changing host-response technologies that can transform patient care”, said Dr Eran Eden, CEO and Co-founder of MeMed. “The recent 510(k) clearance of MeMed BV® by the US Food and Drug Administration (FDA) following a decade of research from concept to impacting patient lives represents the
culmination of this journey. MeMed BV® accurately distinguishes between bacterial and viral infections to improve patient management and is a critical tool in the fight against resistant bacteria. Combining the complementary strengths of our companies and providing access on the LIAISON® will broaden the availability of this pioneering technology for the benefit of patients and society.”

About DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.
More info at www.diasoringroup.com

About MeMed
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. For additional information on MeMed, please visit www.me-med.com.

For additional information, please contact:

**DIASORIN CONTACTS:**

**Riccardo Fava**  
*Corporate VP Communication & Investor Relations*  
Tel: +39.0161.487988  
riccardo.fava@diasorin.it

**Emanuela Salvini**  
*Investor Relator*  
Tel: +39.0161.487567  
emanuela.salvini@diasorin.it

**MEMED CONTACTS:**

**Media:** Will Harris, VP Marketing, MeMed  
pr@me-med.com

**IR:** Kfir Emmer, CFO Finance, MeMed  
kfir.emmer@me-med.com  
Tel +972-4-8500302

**Media relations contact:**  
Consilium Strategic Communications: MeMed@consilium-comms.com